このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

クローン病の管理と治療に役立つ CDPATH™ の研究 (COMPASS-CD)

2026年10月5日 更新者:Takeda

クローン病リスク予測ツールである CDPATH™ の実世界での使用を評価する第 4 相試験

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

研究の種類

介入

入学 (実際)

241

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda、California、アメリカ、92357
        • VA Loma Linda Healthcare System
      • Murrieta、California、アメリカ、92563
        • United Medical Doctors
      • Newport Beach、California、アメリカ、92663
        • University of Southern California Medical Center
      • Orange、California、アメリカ、92868
        • University of California at Irvine Medical Center
      • Orange、California、アメリカ、92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora、Colorado、アメリカ、80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden、Connecticut、アメリカ、06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater、Florida、アメリカ、33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola、Florida、アメリカ、32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls、Idaho、アメリカ、83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights、Illinois、アメリカ、60005
        • GI Alliance
      • Gurnee、Illinois、アメリカ、60031
        • GI Alliance
      • Northbrook、Illinois、アメリカ、60062
        • Comprehensive Gastrointestinal Health
      • Rockford、Illinois、アメリカ、61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University
    • Iowa
      • Clive、Iowa、アメリカ、50325
        • Iowa Digestive Disease Center
      • Iowa City、Iowa、アメリカ、52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge、Louisiana、アメリカ、70809
        • GI Alliance - Baton Rouge
      • Shreveport、Louisiana、アメリカ、71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia、Maryland、アメリカ、21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington、Massachusetts、アメリカ、01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester、Massachusetts、アメリカ、01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87131-0001
        • University of New Mexico
    • New York
      • New York、New York、アメリカ、10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek、Ohio、アメリカ、45431
        • Clinical Inquest Center Ltd
      • Dayton、Ohio、アメリカ、45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland、Oregon、アメリカ、97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill、Pennsylvania、アメリカ、17011
        • Susquehanna Research Group, LLC
      • Pittsburgh、Pennsylvania、アメリカ、15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh、Pennsylvania、アメリカ、15212
        • Allegheny Center for Digestive Health
      • Uniontown、Pennsylvania、アメリカ、15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville、South Carolina、アメリカ、29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City、South Dakota、アメリカ、57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville、Tennessee、アメリカ、37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin、Texas、アメリカ、78712
        • The University of Texas at Austin
      • Houston、Texas、アメリカ、77030
        • Baylor College of Medicine
      • Southlake、Texas、アメリカ、76092
        • GI Alliance - Southlake
    • Utah
      • Ogden、Utah、アメリカ、84403
        • Care Access Research Berkley
      • Salt Lake City、Utah、アメリカ、84132
        • University of Utah
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • GCGA Physicians LLC
      • Lynchburg、Virginia、アメリカ、24502
        • Gastroenterology Associates
    • Washington
      • Bellevue、Washington、アメリカ、98405
        • GI Alliance

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

他の名前:
  • 見込み

Three blood samples will be drawn.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
時間枠:Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
時間枠:Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
時間枠:Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
時間枠:Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
時間枠:Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
時間枠:Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
時間枠:Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
時間枠:Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
時間枠:First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Study Director、Takeda

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年6月25日

一次修了 (実際)

2026年8月27日

研究の完了 (実際)

2026年8月27日

試験登録日

最初に提出

2021年3月19日

QC基準を満たした最初の提出物

2021年3月19日

最初の投稿 (実際)

2021年3月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月8日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • Vedolizumab-4015

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 共有アクセス基準

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。